• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Funds

Astorg gears up for EUR 6.5bn close for Fund VIII next year

  • Min Ho
  • 29 September 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

French sponsor Astorg is aiming to raise EUR 6.5bn for its eighth buyout fund with closing expected by the early part of next year, partner Jean Raby told Unquote.

Astorg VIII was launched late last year with the GP now pitching the strategy to LPs, including existing investors, he said. The fund has received a “good level” of re-ups so far, he added.

Astorg will also be looking to tap up the retail market and high-net-worth individuals markets – a responsibility that Raby, who joined in May, will oversee, he said. Raby was previously CEO of Natixis Investment Managers and head of asset and wealth Management for Natixis, among other companies and roles.

“Progress on retail and HNWI distribution are early days,” he said. “Historically, we’ve worked with family offices, but they make up a minority share of our LPs.”

Its existing LPs are mostly European, although not French-centric, he said, noting that one third of its LPs make up are from US institutions and 15% from Asian investors.

Among LPs in its seventh fund include US-based Teachers’ Retirement System of the State of Illinois, New York State Teachers' Retirement System, as well as France-based Societe Fonciere, Financiere et de Participations and Switzerland-based Pictet Alternative Advisors, among others, according to Unquote data.

The fundraising effort coincides with the close of its EUR 1.3bn mid-market fund earlier this year.

Investments
The Paris-based investor has been busy deploying capital for Fund VIII with four investments announced so far. Among the most significant is the GBP 1.7bn takeover of Euromoney, a UK-based financial news and information business, alongside sponsor peer Epiris. As part of the deal, Astorg will take control of the Fastmarkets unit, which provides price benchmarking and analysis of commodities markets.

While the new flagship fund is expected to be around a third larger than its predecessor, its strategy of investing primarily in B2B businesses across healthcare, technology, industrials and business services will not swerve, said Nicolas Marien, investment partner at Astorg.

Fund VIII is able to provide companies with equity cheques of between EUR 400m-600m across 10-12 companies. Its co-investment capabilities will also allow Astorg to target larger companies, Marien said.

Businesses it typically targets are those which are leaders in their sector, very profitable, with EBITDA margins of around 30%, and high cash conversion rate, he said. It also prefers companies that are able to generate their own growth by their innovation or market penetration, regardless of GDP cycles, Marien added.

“Despite a more challenging environment we want to continue to deploy capital, we want to continue to look at deals… as far as those deals are in line with our investment strategy across industrials, services, tech, and healthcare, which has proven historically to be quite resilient and capable of generating attractive returns across the economic cycle,” Marien said.

With heightened competition for B2B businesses within the M&A market, Astorg typically tries to make itself known to management teams well before any sale processes, allowing it to develop an angle on the business, Marien said.

“This leads to a narrow, targeting exercise in our pipeline, developing a high conviction early on,” Marien said. “When we approach a company, we may have spent a year and a half to two years looking at the target and developing a conviction. That makes for a very powerful conversation with the CEOs and their shareholders.”

Exits
Among Astorg’s latest exits are Autoform, a Swiss engineering software for sheet metal forming simulation, sold to Carlyle in a deal reportedly valued at EUR 1.75bn. It also exited HRA Pharma, a consumer self-care company, to Irish pharma group Perrigo last year for EUR 1.8bn

Meanwhile, Astorg has moved IQ-EQ, a Luxembourg-based fund services provider, into a continuation fund.

“We are very disciplined. When you look at our portfolio today, we have no ‘bottom of the barrel’ portfolio companies," said Raby.

“Some of our peers drag a portfolio company for 12-13-14 years. That's not our case,” he said. “In Astorg, our oldest investment is Echosens invested in 2018,” he said. “Our job is to monetize at some point. We are disciplined in deal activity. So we'll continue exiting.”

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Funds
  • Buyout
  • France
  • Fundraising
  • Astorg Partners

More on Funds

Fund closes in US dollars
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • Funds
  • 05 September 2023
Bettina Curtze of Redalpine
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
Andris K. Berzins of Change Ventures
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • Funds
  • 31 August 2023
Fund launches in euros
Iron Wolf Capital targets EUR 70m for second vehicle

Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups

  • Funds
  • 30 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013